EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Type I interferons in health and disease: molecular aspects and clinical implications

Clio P Mavragani, Mary K Crow iD

Physiological Reviews · 01.10.2025 · 105 (4) · 2537-2587

DOI: 10.1152/physrev.00047.2024 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Physiological Reviews, erschienen am 01.10.2025. Verfasst von Clio P Mavragani und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiology, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece. Hauptthemen laut MEDLINE: Interferon Type I. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 511 Literaturangaben. Gefördert von: Mary K. Crow , Chair in Autoimmunity and Inflammation Research, Research Grant from Spunk Fund, Inc., Research Contract with Gilead Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Type I interferons (IFNs), particularly IFNα and IFNβ, play a crucial role in the human immune response against viral infections. This review delves into the multifaceted antiviral, immunomodulatory, and antitumor physiological roles of type I IFNs, while describing their contribution to the pathogenesis of various disease pathologies including cancer, systemic and organ-specific autoimmunity, neuroinflammation, and atherosclerosis. Genetic determinants influencing activation of type I IFN pathways and therapeutic interventions either targeting or stimulating these pathways in the context of autoimmunity and cancer, respectively, are also discussed. Ultimately, the current understanding of the role of type I IFNs as biomarkers indicative of distinct clinical and serological phenotypes, their correlation with disease activity, their predictive role in therapeutic outcomes across diverse clinical scenarios, as well as the challenges associated with their implementation in clinical practice, are thoroughly addressed. Together, these insights underscore the significant potential of type I IFNs, as mediators and therapeutic targets, to reshape clinical decision-making, while highlighting the urgent need for robust, standardized methodologies for assessment of type I IFNs and their integration into routine practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Interferon Type IHumansAnimalsAutoimmunityNeoplasmsAutoimmune DiseasesVirus Diseases

Stichwörter der Autor:innen

antitumor immunityantiviral immunityautoimmune diseasesneuroinflammationtype I interferons

Substanzen

Interferon Type I

Autor:innen und Institutionen

  • Department of Physiology, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
  • Mary Kirkland Center for Lupus Research, Hospital for Special Surgery and Weill Cornell Medicine, New York, New York, United States.

ORCID-Profile: Mary K Crow

Förderung

  • Mary K. Crow , Chair in Autoimmunity and Inflammation Research
  • Research Grant from Spunk Fund, Inc.
  • Research Contract with Gilead Sciences
  • Mary K. Crow, Chair in Autoimmunity and Inflammation Research

Zitieren

APA

Mavragani, C. P., & Crow, M. K. (2025). Type I interferons in health and disease: molecular aspects and clinical implications. Physiological Reviews, 105(4), 2537-2587. https://doi.org/10.1152/physrev.00047.2024

Vancouver

Mavragani CP, Crow MK. Type I interferons in health and disease: molecular aspects and clinical implications. Physiological Reviews. 2025;105(4):2537-2587. doi:10.1152/physrev.00047.2024

BibTeX
@article{Mavragani2025,
  author = {Mavragani, Clio P and Crow, Mary K},
  title = {Type I interferons in health and disease: molecular aspects and clinical implications},
  journal = {Physiological Reviews},
  year = {2025},
  volume = {105},
  number = {4},
  pages = {2537--2587},
  doi = {10.1152/physrev.00047.2024}
}
Kostenlos starten →